SuperworthMedtronic MDT
- Market cap
- $122B
- PE
- 23.4×
- 10y median 28.2×
- Forward PE
- 15.9×
- 10y median 17.3×
- Price to sales
- 3.3×
- EV/EBIT
- 20.7×
- Revenue, 12 months
- $37.5B
- +10% on a year ago
- Net margin
- 13.9%
- Free cash flow yield
- 5.0%
Medtronic trades at 23.4× trailing earnings, cheaper than 90% of the last ten years. Revenue was $37.5B over the last twelve months, up 10% on a year earlier with a 14% net margin.
Charts
Financials
| Income statement | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $8B+5% | $8.1B+5% | $8.6B+1% | $7.9B+3% | $8.4B+5% | $8.3B+3% | $8.9B+4% | $8.6B+8% | $9B+7% | $9B+9% | $9.8B+10% | $9.8B+14% | |
| Cost of revenue | $2.8B+9% | $2.8B+4% | $3B+2% | $2.8B+5% | $2.9B+7% | $2.8B−0% | $3.1B+3% | $3B+9% | $3.1B+4% | $3.3B+17% | $3.4B+8% | $3.4B+14% |
| Gross profit | $5.2B+3% | $5.3B+5% | $5.5B−0% | $5.2B+2% | $5.5B+5% | $5.5B+4% | $5.8B+4% | $5.6B+8% | $5.9B+8% | $5.8B+4% | $6.4B+11% | $6.3B+14% |
| R&D | $698M+3% | $695M+1% | $675M+5% | $676M+1% | $697M−0% | $675M−3% | $684M+1% | $726M+7% | $754M+8% | $722M+7% | $671M−2% | $771M+6% |
| SG&A | $2.7B+3% | $2.7B+2% | $2.8B+6% | $2.7B+2% | $2.8B+3% | $2.7B+2% | $2.7B−2% | $2.8B+6% | $3B+8% | $3B+9% | $3.1B+12% | $3.2B+14% |
| $1.3B−5% | $1.5B+7% | $1.1B−33% | $1.3B+1% | $1.6B+19% | $1.6B+11% | $1.4B+36% | $1.4B+13% | $1.7B+6% | $1.5B−11% | $1.9B+30% | $1.8B+22% | |
| Interest expense | $180M+53% | $188M+13% | $202M+8% | $167M+13% | $209M+16% | $179M−5% | $174M−14% | $176M+5% | $181M−13% | $181M+1% | $176M+1% | $186M+6% |
| Pre-tax income | $1.3B−6% | $1.5B+7% | $855M−45% | $1.3B+6% | $1.6B+19% | $1.5B+5% | $1.3B+48% | $1.3B+3% | $1.6B+2% | $1.4B−9% | $1.8B+45% | $1.8B+36% |
| $402M−58% | $135M−8% | $197M−46% | $220M−45% | $281M−30% | $237M+76% | $199M+1% | $255M+16% | $215M−24% | $254M+7% | $575M+189% | $289M+13% | |
| Net income | $909M+113% | $1.3B+8% | $654M−45% | $1B+32% | $1.3B+40% | $1.3B−2% | $1.1B+62% | $1B−0% | $1.4B+8% | $1.1B−12% | $1.2B+18% | $1.5B+41% |
| $0.68+113% | $0.99+8% | $0.49−44% | $0.80+36% | $0.99+46% | $1.01+2% | $0.82+67% | $0.81+1% | $1.07+8% | $0.89−12% | $0.97+18% | $1.14+41% | |
| 1.3B+0% | 1.3B+0% | 1.3B−1% | 1.3B−3% | 1.3B−3% | 1.3B−3% | 1.3B−3% | 1.3B−1% | 1.3B+0% | 1.3B+0% | 1.3B+0% | 1.3B−0% |
Gross profit: 73 periods, Q1 FY09 to Q1 FY27: not printed by the filing, worked out from its own lines.
Operating income: 24 periods, Q1 FY09 to Q4 FY14: not printed by the filing, worked out from its own lines.
EPS, diluted: 8 periods, Q4 FY09 to Q4 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: 17 periods, Q4 FY09 to Q4 FY26: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY15: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q2 FY27 | $9.5B | $9.4B to $9.5B | $1.33 | $1.31 to $1.40 | 16 |
| Q3 FY27 | $9.5B | $9.4B to $9.6B | $1.43 | $1.41 to $1.45 | 16 |
| Q4 FY27 | $10.3B | $10.2B to $10.4B | $1.78 | $1.76 to $1.80 | 12 |
| Q1 FY28 | $9.8B | $9.7B to $9.9B | $1.47 | $1.46 to $1.49 | 9 |
| Q2 FY28 | $10B | $9.9B to $10.1B | $1.48 | $1.47 to $1.50 | 7 |
| Q3 FY28 | $10B | $9.9B to $10.1B | $1.54 | $1.53 to $1.56 | 8 |
| Q4 FY28 | $10.8B | $10.7B to $10.9B | $1.88 | $1.86 to $1.90 | 13 |
| Q1 FY29 | $10B | $10B to $10.1B | $1.52 | $1.51 to $1.54 | 10 |
Peers
Companies in Medical - Devices nearest Medtronic's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MDTMedtronic | $122B | 23.4× | 28.2× | 15.9× | 3.3× | +10% | 13.9% |
| SYKStryker | $117.8B | 31.8× | 41.2× | 19.3× | 4.6× | +8% | 14.4% |
| ABTAbbott Laboratories | $179.4B | 38.7× | 36.7× | 17.7× | n/m | n/m | n/m |
| BSXBoston Scientific | $66.2B | 18.5× | 67.0× | 14.1× | 3.2× | +14% | 17.5% |
| EWEdwards Lifesciences | $51.3B | 51.2× | 40.3× | 28.3× | 7.9× | +15% | 15.4% |
| GEHCGE HealthCare Technologies | $32.3B | 16.4× | 17.0× | 13.8× | 1.5× | +7% | 9.3% |
| DXCMDexCom | $29.4B | 30.9× | 102× | 27.7× | 5.9× | +16% | 20.1% |
| ZBHZimmer Biomet | $18.8B | 24.0× | 31.4× | n/m | 2.2× | +9% | 9.5% |
| Peer median | $51.3B | 30.9× | 40.3× | 18.5× | 3.9× | +11% | 14.9% |
Investors who own it
Investors we follow who held Medtronic at the end of Jun 30, 2026, from their 13F filings.
- Baillie GiffordBaillie Gifford0.0% of portfolioadded
More on Medtronic
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #3of 33Healthcare stocks with the highest dividend yields
- #4of 13Medical device stocks with the highest free cash flow yield
- #5of 13Medical device stocks with the lowest EV/EBIT
- #5of 13Medical device stocks with the lowest PE ratio
- #7of 17Medical device stocks with the highest profit margins
- #7of 12Medical device stocks with the fastest earnings growth
- #10of 17Medical device stocks with the fastest revenue growth
Its groups
About
- Industry
- Medical - Devices
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .